Automated Pupillometry Could Point to Autonomic Dysfunction in Acromegaly Automatic pupillometry could serve as a non-invasive method for monitoring autonomic dysfunction in patients with acromegaly.

Automated pupillometry could serve as a noninvasive tool to identify early neurological or autonomic nervous system (ANS) dysfunction in patients with #Acromegaly. Study in BMC Ophthalmology.

Learn more: https://bit.ly/4bRCC1P

#RareDisease #Ophthalmology #MedSky

Facial Analysis in Acromegaly Using Machine Learning: Toward Earlier Diagnosis AbstractContext. Acromegaly is a rare and progressive disorder often diagnosed late due to its insidious onset and gradually evolving facial features. Earl

Facial Analysis in Acromegaly Using Machine Learning: Toward Earlier Diagnosis Get access Arrow. Read more in #JCEM: bit.ly/3NdrwvH #acromegaly #MachineLearning #FacialAnalysis @endocrinesociety.bsky.social

GM3 Accumulation May Be Connected to Insulin Resistance in Acromegaly Findings suggest GM3-mediated membrane changes may disrupt insulin signaling and contribute to insulin resistance in acromegaly.

#SfEBES2026: Growth hormone and IGF-1 exposure impaired insulin signaling in adipocytes by reducing AKT phosphorylation.

Read more: https://bit.ly/40WwtvZ

#RareDisease #Endocrinology #Acromegaly

Monthly CAM2029 Maintains Stable and Extended Acromegaly Control CAM2029 maintained biochemical and symptom control in acromegaly across a 4-week dosing interval, including delays beyond 28 days.

#CAM2029 maintained stable biochemical and symptom control throughout a 4-week dosing interval in patients with #Acromegaly, including among those whose assessments occurred more than 28 days after dosing.

Learn more: https://bit.ly/46zeUp9

#RareDisease #MedSky

Disease Control Reverses Growth Hormone-Driven Fibrosis in Acromegaly Disease control in acromegaly reduced adipose and skeletal muscle fibrosis, supporting reversibility of GH-driven remodeling.

Disease control in #Acromegaly reverses growth hormone (GH)-driven fibrosis in adipose and skeletal muscle tissue, accompanied by marked reductions in systemic collagen turnover and fibroblast activation protein α (FAPα) activity. Research in @eurojendo.bsky.social

Read more: https://bit.ly/4skfI9A

Case Report: Extensive Skin Tags Serve as Clues to MEN1-Linked Acromegaly Numerous or extensive acrochordons may signal underlying acromegaly or MEN1 and should prompt targeted GH, IGF-1, and insulin testing.

Extensive #Acrochordons may represent a critical cutaneous clue to multiple endocrine neoplasia type 1 (#MEN1) and concomitant #Acromegaly. Case report in The American Journal of Medicine.

Read here: https://bit.ly/4rE0CvY

#RareDisease #MedSky

Large Decoy Lesions in Acromegaly May Mask Smaller Active Pituitary Lesions Larger "decoy lesions" may mask smaller pituitary lesions that are actually responsible for cases of acromegaly or Cushing's syndrome.

A large, radiologically dominant “decoy” lesion can sometimes mask smaller lesions that are truly responsible for driving hormonal hypersecretion in cases of #Acromegaly or Cushing’s syndrome. Study in World Neurosurgery.

Read more: https://bit.ly/46YDnEi

#RareDisease #Neurology #MedSky

Gender differences in the glycometabolic and cardiovascular features of acromegaly A gender-medicine driven management approach should be considered for acromegaly. Women tend to have a longer diagnostic delay than men and a worse glycometabolic profile, but milder cardiac…

A gender-medicine driven management approach should be considered for #acromegaly.

Women tend to have a longer diagnostic delay than men and a worse glycometabolic profile, but milder cardiac abnormalities despite higher CV mortality.

👉 buff.ly/QNEzbBp

#CardioSky

Lipidomic Signatures Reveal Disease Severity and Cardiac Risk in Acromegaly SM 34:0;O2 and phosphorylcholine robustly distinguish acromegaly from controls and track biochemical disease activity.

#Acromegaly is characterized by a distinct serum lipidomic signature in which #Sphingomyelin (SM) 34:0;O2 and phosphorylcholine emerge as discriminative biomarkers, with SM 34:0;O2 reflecting disease activity and treatment status.

Read more: https://bit.ly/3OmdhEQ

Acromegaly May Lead to Airway Obstruction Through CAJ Arthropathy Cricoarytenoid joint arthropathy may be the initial presenting feature of acromegaly, according to a case study of a 72-year-old man.

Arthropathy of the cricoarytenoid joint (#CAJ), leading to significant glottic obstruction, can be the initial presenting sign of #Acromegaly. Study in Laryngoscope

Read more: https://bit.ly/49OW1kc

#RareDisease #GlotticObstruction #MedSky

Intraoperative Tumor Consistency Predicts Remission in Acromegaly Intraoperative tumor consistency strongly predicted histopathological subtype and remission in patients with acromegaly.

Surgeons can predict both prognosis and histopathological subtype of pure somatotroph adenomas of #Acromegaly by observing intraoperative tumor consistency, enabling patient-specific surgical strategies that improve remission.

Read more: https://bit.ly/3LZCynE

#RareDisease #MedSky

Cabergoline-Induced Gambling Causing Increased Adrenal Crisis Episodes Abstract. Dopamine agonists have been used in the treatment of acromegaly, but they are modestly effective and are rarely associated with impulse control d

Cabergoline-Induced Gambling Causing Increased Adrenal Crisis Episodes. Read more in #JCEMCaseReports: bit.ly/4pNVtj6 #acromegaly #DopamineAgonists #CabergolineImpulseControlDisorders @endocrinesociety.bsky.social

FDA Accepts NDA Resubmission for CAM2029 for Patients With Acromegaly The FDA has accepted a resubmitted NDA for CAM2029, a long-acting subcutaneous octreotide formulation for the treatment of acromegaly.

The @fda.gov has accepted a resubmitted New Drug Application (#NDA) for #CAM2029 (Oclaiz™), a long-acting subcutaneous octreotide formulation for the treatment of #Acromegaly, according to a news release from Camurus.

Read more: https://bit.ly/45YO9tJ

#RareDisease #MedSky #Oclaiz

Sleep Quality and Apnea Hypopnea Index Improve After Acromegaly Treatment In acromegaly, AHI and PSQI improved after treatment, while IGF-1 normalization was achieved in only one-third of patients.

In patients with #Acromegaly, apnea hypopnea index (#AHI) and subjective sleep quality improved significantly after treatment, according to a prospective study from India published in Endocrine Research.

Read more: https://bit.ly/45ECyA0

#RareDisease #Endocrinology

Camurus Receives FDA Green Light for Oclaiz™ to Combat Acromegaly Camurus announces that the FDA has accepted its NDA resubmission for Oclaiz™, an innovative treatment for acromegaly, with a target decision date set for June 2026.

Camurus Receives FDA Green Light for Oclaiz™ to Combat Acromegaly #Sweden #Lund #Camurus #Acromegaly #Oclaiz™

Despite Treatment, Patients With Acromegaly Report Disease and QoL Burden Patients with acromegaly report disease burden beyond symptoms, including negative effects on activities of daily living and productivity.

Despite currently available medical therapies, patients with #Acromegaly report a substantial burden beyond symptoms, including negative effects on activities of daily living and work productivity. Results in Journal of Patient-Reported Outcomes.

Read more: https://bit.ly/48UeSsb

#RareDisease

Reimagining Biomarkers and Paving the Way to Precision Therapy in Acromegaly Advances in molecular profiling are beginning to map the biological individuality of each tumor and anticipate treatment response.

Advances in molecular profiling are beginning to map the biological individuality of each tumor and anticipate treatment response.

Learn more: https://bit.ly/3KjqQUc

#RareDisease #Acromegaly #GrowthHormone #InsulinLikeGrowthFactor1

Effects of Acromegaly and Its Therapies on Bone Metabolism and Fracture Risk Skeletal fragility is common in individuals with active or uncontrolled acromegaly, and therapy choice may be altered to decrease risk.

Skeletal fragility is common in individuals with active or uncontrolled #Acromegaly, and therapy choice may be altered to decrease risk.

Learn more: https://bit.ly/4rBMG60

#RareDisease #GrowthHormone #InsulinLikeGrowthFactor1 #MedSky

AVA Dilation With Reduced Excursion Is Common in Acromegaly Increased global LV circumferential strain was observed in patients with active acromegaly vs inactive disease or healthy controls.

Significant dilation of the aortic valve annulus (AVA) is common in #Acromegaly, often accompanied by a reduced motion of the valve ring, according to a Hungarian study published in the Journal of Clinical Medicine.

Read more: https://bit.ly/4a3jvSR

#RareDisease #MedSky

Early Retinal Nerve and Vascular Damage Detected in Acromegaly Patients with newly diagnosed acromegaly exhibit early retinal nerve and microvascular damage, independent of optic chiasm compression.

Patients with newly diagnosed #Acromegaly show early #RetinalNerve and #VascularDamage, even without pituitary tumor compression of the optic chiasm. Study in Pituitary

Read more: https://bit.ly/3Wvh8jU

#RareDisease #Endocrinology #Ophthalmology #PituitaryTumor

Growth Hormone Assay-Adjusted Standardization Reveals Distinct Clinical Phenotypes in Acromegaly To identify distinct clinical phenotypes in acromegaly based on GH assay standardization and unsupervised machine learning.

Distinct clinical phenotypes in #acromegaly. GHxULN complements IGF-1 by revealing differences in tumor behavior, age, and comorbidities. @endocrinesociety.bsky.social @socendocrinology.bsky.social @sociedadseen.bsky.social @pituitarysociety.bsky.social 👇
www.endocrinepractice.org/article/S153...

Endocrinology Weekly Update – September 2nd 2025 🧬 Endocrinology Update: Denosumab Approved, New Thyroid Guidelines, AI in Diabetes Care and More From AI breakthroughs and next-gen diabetes […] The post Endocrinology Weekly Update – September 2nd 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Endocrinology Weekly Update – September 2nd 2025 #News #Acromegaly #AIinhealthcare #clinicalresearch Comment below!

Endocrinology Weekly Update – September 2nd 2025 🧬 Endocrinology Update: Denosumab Approved, New Thyroid Guidelines, AI in Diabetes Care and More From AI breakthroughs and next-gen diabetes […] The post Endocrinology Weekly Update – September 2nd 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Endocrinology Weekly Update – September 2nd 2025 #News #Acromegaly #AIinhealthcare #clinicalresearch Comment below!

Endocrinology Weekly Update – September 2nd 2025 🧬 Endocrinology Update: Denosumab Approved, New Thyroid Guidelines, AI in Diabetes Care and More From AI breakthroughs and next-gen diabetes […] The post Endocrinology Weekly Update – September 2nd 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Endocrinology Weekly Update – September 2nd 2025 #News #Acromegaly #AIinhealthcare #clinicalresearch Comment below!

Camurus Receives Green Light for Oczyesa® to Treat Acromegaly in the UK Camurus’ Oczyesa®, a treatment for acromegaly, has been approved by the UK MHRA, offering a new option for adult patients. Launch expected in late 2025.

Camurus Receives Green Light for Oczyesa® to Treat Acromegaly in the UK #United_Kingdom #Lund #Camurus #Acromegaly #Oczyesa®

EndoBridge 2024: pearls and highlights Explore key insights from EndoBridge 2024. Covering a broad range of conditions, from acromegaly, thyroid disease, and osteoporosis, to obesity, premature ovarian failure, and male infertility.

What were the key insights from EndoBridge 2024?

Explore a broad range of conditions, from #acromegaly, thyroid disease, and #osteoporosis, to #obesity, premature ovarian failure, and male infertility.

👉 buff.ly/HkzqsTc

#EndoSky

Endocrinology Weekly Update – August 5th 2025 🧬 Endocrinology Update: Weekly Growth Hormone Approved, New T1D Subtype, AI Finds Hidden Risk and More From AI-driven diabetes detection […] The post Endocrinology Weekly Update – August 5th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Endocrinology Weekly Update – August 5th 2025 #News #Acromegaly #AIinhealthcare #DiabetesResearch Comment below!

Figure outlining a holistic person-centred approach to management of acromegaly-related diabetes mellitus.

In this Review, Daniela Esposito et al discuss the pathophysiology, clinical challenges and management of #diabetes mellitus in patients with #acromegaly (£) bit.ly/3HkGAVp #EndoSky #MedSky

Measuring the burden of acromegaly: a cross-population perspective on utilization, costs, and care gaps | Becaris Publishing

Measuring the burden of #acromegaly: a cross-population perspective on utilization, costs, and care gaps | @crinetics.bsky.social becarispublishing.com/digital-cont...

Endocrinology Weekly Update – August 5th 2025 🧬 Endocrinology Update: Weekly Growth Hormone Approved, New T1D Subtype, AI Finds Hidden Risk and More From AI-driven diabetes detection […] The post Endocrinology Weekly Update – August 5th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Endocrinology Weekly Update – August 5th 2025 #News #Acromegaly #AIinhealthcare #DiabetesResearch Comment below!